Clinical Evaluation in Practice – More Than Just a Clinical Evaluation Report
Hardly any regulatory requirement of the MDR is underestimated as often as clinical evaluation. It is one of the key obligations for nearly all medical devices, yet in practice it is often reduced to the preparation of a single document: the Clinical Evaluation Report (CER). However, anyone who treats the clinical evaluation as a mere documentation task runs the risk of failing to meet the regulation’s actual requirements.
In fact, it is a continuous process that spans the entire product life cycle. It is closely intertwined with risk management, post-market surveillance (PMS), post-market clinical follow-up (PMCF), and technical documentation. The CER is merely the visible tip of the iceberg—a written snapshot of a process that continues uninterrupted.
Teilen Sie diesen Beitrag:
Teilen Sie diesen Beitrag:
The Legal Framework: Article 61 and Annex XIV of the MDR
The legal basis for clinical evaluation is, in particular, Article 61 of the MDR and Annex XIV of the MDR. The Regulation defines clinical evaluation as a systematic and planned process for the continuous generation, collection, analysis, and assessment of clinical data on a product. The objective is to demonstrate that a medical device meets the essential safety and performance requirements, achieves its intended performance, and has a favorable benefit-risk ratio.
Annex XIV explicitly requires two components: a clinical evaluation plan and a report based on that plan. The evaluation must be thorough and objective—that is, it must take into account both favorable and unfavorable data—and its depth and scope must be commensurate with the product’s risk class. In addition, all statements and claims made by the manufacturer—for example, in instructions for use, on product labels, or in marketing materials—must be supported by appropriate clinical data.
Finding the Right Evidence Strategy
The real challenge begins with a seemingly simple question: What data convincingly demonstrates the safety and performance of this specific product? There is no one-size-fits-all answer. Depending on the risk class, degree of innovation, available literature, existing clinical data, and the state of the art, a wide variety of sources may be relevant.
The following are available: proprietary clinical data, critically evaluated scientific literature, data on demonstrably equivalent products, and findings from PMS and PMCF activities. In certain cases, non-clinical data can also make a significant contribution, provided that its relevance is clearly justified. The equivalence route, in particular, is challenging: The MDR requires that the comparator product be technically, biologically, and clinically similar and that the manufacturer can demonstrate sufficient access to its data. A sound evidence strategy therefore establishes early on which sources will be combined and where, if necessary, proprietary data must be collected.
Clinical Evaluation as a Continuous Process
A common mistake in practice is to update the clinical evaluation only shortly before certification or recertification. However, the MDR takes an explicitly lifecycle-oriented approach. New findings from complaints, vigilance reports, market observations, scientific publications, or PMCF activities must be continuously evaluated and, if necessary, incorporated into the clinical evaluation.
The CER is merely a documented summary of an ongoing assessment process. Anyone who views it as an endpoint misunderstands the logic of the regulation: The evaluation does not end with the signing of the report, but is updated with every new data point from the market. It is precisely this up-to-date nature that Notified Bodies now scrutinize much more critically than they did under the previous Medical Devices Directive.
State of the Art – The Often Underestimated Benchmark
Particular importance is attached to the so-called “state of the art”—the current level of medical and technical knowledge. Manufacturers must not only demonstrate the safety and performance of their own product, but also contextualize it within established procedures and available alternatives. A product may be safe and effective in and of itself, yet still fall short of expectations when compared to today’s standards.
Clinical evaluation is therefore not merely a documentation task in and of itself, but rather a tool for continuously assessing a product’s regulatory and clinical acceptance. It compels manufacturers to regularly assess their own product portfolio in light of advances in the field.
From a Mandatory Document to a Strategic Tool
For manufacturers, all of this means one thing above all else: clinical evaluation, risk management, PMS, and PMCF must be viewed as an integrated system, not as separate, parallel tasks. Risk management formulates hypotheses that clinical evaluation must either confirm or refute. PMS collects all market data, while PMCF specifically fills in gaps in clinical evidence. The results feed back into one another.
Only when these processes are integrated can MDR requirements be met efficiently while simultaneously generating robust evidence of safety, performance, and clinical benefit. In this way, clinical evaluation evolves from a regulatory formality into a strategic tool for sustainable market and certification security. This is exactly where BAYOOCARE comes in: Together with manufacturers, we develop an evidence strategy tailored to the risk class and target markets, and we support the clinical evaluation throughout its entire lifecycle—from initial planning to ongoing maintenance.
